Lactose Intolerance Market

 Market Overview:

The 7 major lactose intolerance markets reached a value of USD 11.37 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 22.18 Billion by 2035, exhibiting a growth rate (CAGR) of 6.27% during 2025-2035.

The lactose intolerance market has been comprehensively analyzed in IMARC's new report titled "Lactose Intolerance Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Lactose intolerance refers to a digestive disorder caused by an inability to digest lactose, a major carbohydrate found in dairy products. This ailment is characterized by a deficiency in the enzyme lactase, which is required in the body to digest lactose. Depending on the causative factor, there are four types of lactose intolerance: primary, secondary, congenital, and developmental. The most common symptoms of the ailment include bloating, gas, diarrhea, abdominal cramps, nausea, etc. Typically, these indications appear one and a half to two hours after consuming milk-based foods or drinks. Individuals suffering from this condition may also experience an urgent need to go to the toilet, lower belly pain, vomiting, and constipation. The diagnosis of this condition involves a review of the patient's medical history, symptoms, and physical examination. The other supporting tests to confirm a diagnosis include a stool acidity test and a hydrogen breath test. Additionally, the healthcare provider may perform a lactose tolerance test to detect the absorbance of lactose in the digestive system by measuring blood glucose levels.

The increasing prevalence of genetic disorders on account of inherited gene mutations and structural defects is primarily driving the lactose intolerance market. Apart from this, the rising incidences of intestinal ailments, such as celiac disease, carcinoid syndrome, Crohn's disease, etc., which damage the cells that generate lactase, are also bolstering the market growth. Furthermore, the escalating usage of prescription medications, including rifaximin, to treat bacterial overgrowth in the small intestine that can exacerbate lactose intolerance indications, is creating a positive outlook for the market. Besides this, the widespread adoption of gut microbiome analysis for identifying specific bacteria that may be causing symptoms and guiding personalized treatment options, is acting as another significant growth-inducing factor. Moreover, numerous key players are making extensive investments in research activities to develop safer and cost-effective targeted therapies with a better understanding of disease pathology. This, in turn, is also propelling the market growth. Additionally, the growing demand for lactase enzyme supplements owing to their several associated benefits, including reduced symptoms, improved nutrient absorption, being well-tolerated with fewer side effects, easy availability, etc., is expected to drive the lactose intolerance market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the lactose intolerance market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for lactose intolerance and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lactose intolerance market in any manner.

Recent Developments:

• In February 2024, Novartis announced that Xolair (omalizumab) has been approved by the US FDA to reduce allergic reactions, including anaphylaxis, that can occur after accidental ingestion of one or more foods in pediatric and adult and patients aged 1 year and above with IgE-mediated food allergy. The approval is based on findings from the NIH-sponsored Phase III OUtMATCH research, which demonstrated a considerably higher proportion of food allergy patients as young as one year treated with Xolair could tolerate tiny amounts of peanut, milk, egg, and cashew without an allergic reaction, compared to placebo.

Key Highlights:

• About 65 percent of the human population has a diminished capability to digest lactose after infancy.
• Lactose intolerance is most common in persons of East Asian heritage, with 70 to 100 percent of those affected in these cultures.
• 80 percent of all Native Americans and African-Americans are lactose intolerant.
• Lactose intolerance appears to be more prevalent in patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) than in healthy persons.
• Lactose intolerance typically manifests in adults between the ages of 20 and 40.

Drugs:

Tilactase is a beta-D-galactosidase isolated from Aspergillus oryzae. The medication is used to treat the symptoms of lactose intolerance in babies and older patients who require parenteral nourishment or a fluid diet. It is produced as a chewable tablet that must be taken before consuming a lactose-containing meal.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the lactose intolerance market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the lactose intolerance market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current lactose intolerance marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the lactose intolerance market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the lactose intolerance market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the lactose intolerance market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of lactose intolerance across the seven major markets?
• What is the number of prevalent cases (2019-2035) of lactose intolerance by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of lactose intolerance by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of lactose intolerance by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with lactose intolerance across the seven major markets?
• What is the size of the lactose intolerance patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of lactose intolerance?
• What will be the growth rate of patients across the seven major markets?
   

Lactose Intolerance: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for lactose intolerance drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lactose intolerance market?
• What are the key regulatory events related to the lactose intolerance market?
• What is the structure of clinical trial landscape by status related to the lactose intolerance market?
• What is the structure of clinical trial landscape by phase related to the lactose intolerance market?
• What is the structure of clinical trial landscape by route of administration related to the lactose intolerance market?